Amylyx Pharmaceuticals (AMLX) Equity Average (2021 - 2026)

Amylyx Pharmaceuticals' Equity Average history runs 6 years deep, the most recent figure standing at $289.2 million for Q1 2026.

• In Q1 2026, Equity Average rose 57.96% year-over-year to $289.2 million; the TTM figure through Mar 2026 stood at $289.2 million (up 57.96% YoY), while the FY2025 annual figure was $235.0 million, down 21.43% from the prior year.
• Equity Average was $289.2 million for Q1 2026 at Amylyx Pharmaceuticals, down from $318.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $425.9 million in Q4 2023 to a low of $44.9 million in Q1 2022.
• Historically, Equity Average has averaged $266.1 million across 5 years, with a median of $249.9 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Equity Average soared 672.19% in 2023, then sank 57.62% in 2024.
• A 5-year view of Equity Average shows it stood at $242.3 million in 2022, then jumped by 75.77% to $425.9 million in 2023, then tumbled by 57.62% to $180.5 million in 2024, then soared by 76.54% to $318.6 million in 2025, then slipped by 9.23% to $289.2 million in 2026.
• The last three Equity Average figures came in at $289.2 million (Q1 2026), $318.6 million (Q4 2025), and $249.9 million (Q3 2025), per Business Quant data.